Abstract

Emilio García Toro *, Azcárraga Cuarón , Guillermo Chávez Jr. and Agustín Azcárraga

This study aims to determine the effect of the boosted bufo-toxin towards epileptic symptomatology induced through bufo-toxin in the strains known as BALB/c and Wistar in order to break into the symptomatology which confers lethality to this toxin. The bufo- toxin was maintained in alcoholic solution and applied to rats in doses of 5 to 5-20 units via intramuscular insulin syringe, and observations were recorded. When the rats in question died, a necropsy was performed in order to finally describe the effect of the toxin to the internal organs. Subsequently, the bufo-toxin was boosted and administered at 7, 12 and 30 CH according to the rat strains, and observations were carried out. The rats that were inoculated with 20 units of the named toxin show epileptic symptomatology and finally died from brain stroke or heart attack. However, when administering the bufo-toxin boosted at the 7 CH, such pathogenic symptomology disappears and mortality in rats decreased to 48%. The more effective homeopathic potency was the 7 CH. This model can be used to investigate useful drugs against epilepsy and even heart diseases; the homeopathic medicine at 7 CH acts immediately regarding potencies 12 and 30 CH. The boosted toxin reduces the pathogenic symptomology generated by the bufo-toxin in both rat strains and intervenes in reducing mortality from such effect.